NASDAQ:MYL - Mylan Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: N/A
Consensus Price Target: $0.00
Forecasted Upside: NaN
Number of Analysts: 0
Breakdown:
0 Sell Ratings
0 Hold Ratings
0 Buy Ratings
0 Strong Buy Ratings

^$0.00 As of 02/10/2021 01:00 AM ET

+0.30 (1.20%)

Get New Mylan Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for MYL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MYL

^$0.00

This price target is based on 0 analysts offering 12 month price targets for Mylan in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Mylan. This rating has held steady since October 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
5 buy ratings
6 hold ratings
0 sell ratings

Ratings as of

7/27/2020

0 strong buy ratings
4 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

10/25/2020

0 strong buy ratings
3 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

1/23/2021

0 strong buy ratings
2 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

4/23/2021

0 strong buy ratings
1 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

7/22/2021

0 strong buy ratings
0 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

10/20/2021

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

12/19/2021

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

1/18/2022

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
10/28/2020	Wells Fargo & Company	Lower Price Target	Equal Weight	$17.00 ➝ $16.00	Medium
9/8/2020	Raymond James	Reiterated Rating	Buy		High
8/11/2020	UBS Group	Boost Price Target	Neutral	$17.00 ➝ $18.00	Medium
5/13/2020	UBS Group	Boost Price Target	Neutral	$16.00 ➝ $17.00	High
5/12/2020	Royal Bank of Canada	Reiterated Rating	Buy	$26.00	High
4/30/2020	Wells Fargo & Company	Lower Price Target	Equal Weight	$23.00 ➝ $18.00	Low
4/15/2020	Piper Sandler	Lower Price Target	Neutral	$23.00 ➝ $17.00	Low
4/2/2020	Morgan Stanley	Lower Price Target	Equal Weight	$23.00 ➝ $18.00	High
3/27/2020	Royal Bank of Canada	Lower Price Target	Outperform	$27.00 ➝ $26.00	Low
2/5/2020	SunTrust Banks	Reiterated Rating	Buy	$27.00	Medium
1/9/2020	Piper Sandler	Initiated Coverage	Neutral	$21.00	Medium
1/6/2020	Royal Bank of Canada	Boost Price Target	Outperform	$25.00 ➝ $27.00	High
12/16/2019	Evercore ISI	Reiterated Rating	Buy		Medium
11/27/2019	Cfra	Upgrade	Hold		Low
11/7/2019	Morgan Stanley	Downgrade	Overweight ➝ Equal	$25.00 ➝ $18.00	Low
11/5/2019	Cfra	Downgrade	Hold ➝ Sell		High
9/12/2019	SunTrust Banks	Boost Price Target	Buy	$25.00 ➝ $27.00	Low
8/9/2019	Evercore ISI	Reiterated Rating	Buy		N/A
7/31/2019	Citigroup	Set Price Target	Buy	$26.00	Low
7/31/2019	Credit Suisse Group	Reiterated Rating	Buy	$34.50	Low
7/30/2019	Mizuho	Boost Price Target	Neutral	$25.00 ➝ $27.00	Low
7/30/2019	Morgan Stanley	Reiterated Rating	Overweight	$22.00 ➝ $25.00	Low
7/19/2019	Wolfe Research	Initiated Coverage	Outperform ➝ Outperform	$27.00	Low
7/15/2019	Morgan Stanley	Set Price Target	Buy	$22.00	Low
6/12/2019	Cantor Fitzgerald	Lower Price Target	Neutral	$31.00 ➝ $18.00	Low
6/11/2019	Barclays	Initiated Coverage	Overweight ➝ Overweight	$26.00	Medium
5/28/2019	UBS Group	Lower Price Target	Neutral	$23.00	Low
5/14/2019	Mizuho	Reiterated Rating	Hold		Medium
5/8/2019	Morgan Stanley	Set Price Target	Buy	$32.00	Medium
5/8/2019	Raymond James	Set Price Target	Buy	$31.00	Medium
5/8/2019	BMO Capital Markets	Set Price Target	Buy	$36.00	Medium
5/8/2019	Royal Bank of Canada	Lower Price Target	Outperform	$26.00	Low
5/7/2019	Wells Fargo & Company	Downgrade	Outperform ➝ Market Perform	$33.00 ➝ $22.00	Low
4/1/2019	Cantor Fitzgerald	Reiterated Rating	Hold	$41.00	High
3/27/2019	Argus	Lower Price Target	Buy	$32.00	Medium
3/19/2019	SunTrust Banks	Initiated Coverage	Buy ➝ Buy	$35.00	Low
3/7/2019	UBS Group	Reiterated Rating	Neutral	$31.00	Low
3/6/2019	Credit Suisse Group	Reiterated Rating	Buy	$37.00	Low
3/6/2019	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight	$35.00	Medium
2/27/2019	Wells Fargo & Company	Lower Price Target	Outperform	$40.00 ➝ $33.00	High
2/27/2019	BTIG Research	Lower Price Target	Buy	$35.00	High
2/27/2019	BMO Capital Markets	Boost Price Target	Outperform	$40.00	High
2/27/2019	Sanford C. Bernstein	Downgrade	Outperform ➝ Market Perform	$33.00	High
1/31/2019	Mizuho	Reiterated Rating	Neutral		High
1/23/2019	UBS Group	Downgrade	Buy ➝ Neutral	$54.00 ➝ $32.00	Medium
11/20/2018	Cantor Fitzgerald	Reiterated Rating	Hold	$41.00	Low
11/15/2018	Argus	Upgrade	Hold ➝ Buy	$42.00	Medium
11/6/2018	JPMorgan Chase & Co.	Set Price Target	Buy	$45.00	Low
11/6/2018	Wells Fargo & Company	Upgrade	Market Perform ➝ Buy	$40.00	High
11/6/2018	Royal Bank of Canada	Lower Price Target	Outperform ➝ Buy	$51.00 ➝ $50.00	High
11/6/2018	Morgan Stanley	Boost Price Target	Equal Weight ➝ Hold	$36.00 ➝ $39.00	High
11/6/2018	Citigroup	Lower Price Target	Buy ➝ Buy	$48.00 ➝ $44.00	High
11/6/2018	Cowen	Set Price Target	Hold	$31.00	High
11/6/2018	Bank of America	Upgrade	Neutral ➝ Buy	$44.00 ➝ $42.00	High
11/5/2018	Cantor Fitzgerald	Reiterated Rating	Hold	$41.00	High
10/9/2018	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$46.00 ➝ $36.00	Low
10/5/2018	Mizuho	Downgrade	Buy ➝ Neutral		Low
8/24/2018	Evercore ISI	Upgrade	In-Line ➝ Outperform		Low
8/15/2018	Wells Fargo & Company	Reiterated Rating	Hold		Low
8/13/2018	Royal Bank of Canada	Upgrade	Sector Perform ➝ Outperform	$53.00	Low
8/9/2018	Citigroup	Lower Price Target	Buy ➝ Buy	$50.00 ➝ $48.00	High
8/9/2018	SVB Leerink	Lower Price Target	Outperform	$53.00 ➝ $47.00	High
8/9/2018	Raymond James	Downgrade	Strong-Buy ➝ Outperform		High
8/9/2018	Cowen	Reiterated Rating	Hold	$31.00	High
8/8/2018	Cantor Fitzgerald	Reiterated Rating	Hold	$41.00	High
8/8/2018	Wells Fargo & Company	Set Price Target	Hold	$41.00	High
8/8/2018	Mizuho	Reiterated Rating	Buy	$54.00	High
8/2/2018	Wells Fargo & Company	Reiterated Rating	Hold		Low
7/25/2018	Wells Fargo & Company	Reiterated Rating	Hold		Medium
6/29/2018	Cantor Fitzgerald	Set Price Target	Hold	$41.00	Medium
6/14/2018	Guggenheim	Reiterated Rating	Buy	$59.00	Medium
6/6/2018	Guggenheim	Reiterated Rating	Buy	$59.00	Medium
5/31/2018	Wells Fargo & Company	Set Price Target	Market Perform ➝ Hold	$43.00 ➝ $41.00	High
5/29/2018	Bank of America	Lower Price Target	Neutral ➝ Neutral	$43.00 ➝ $42.00	Medium
5/23/2018	JPMorgan Chase & Co.	Set Price Target	Buy	$53.00	Low
5/9/2018	Cantor Fitzgerald	Set Price Target	Hold	$41.00	Low
4/23/2018	Wells Fargo & Company	Reiterated Rating	Hold		Low
4/12/2018	JPMorgan Chase & Co.	Set Price Target	Buy	$53.00	Low
4/12/2018	SVB Leerink	Upgrade	Market Perform ➝ Outperform	$44.00	Low
4/11/2018	Cantor Fitzgerald	Set Price Target	Hold	$41.00	Medium
4/9/2018	Morgan Stanley	Set Price Target	Buy	$50.00	High
4/3/2018	Royal Bank of Canada	Set Price Target	Hold	$45.00	Low
3/15/2018	Mizuho	Boost Price Target	Buy	$45.00 ➝ $51.00	Low
3/6/2018	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight	$39.00 ➝ $50.00	Medium
3/1/2018	UBS Group	Set Price Target	Buy	$54.00	High
3/1/2018	Cantor Fitzgerald	Set Price Target	Hold	$41.00	Medium
2/16/2018	JPMorgan Chase & Co.	Set Price Target	Buy	$53.00	Low
1/25/2018	Susquehanna Bancshares	Reiterated Rating	Positive ➝ Positive	$47.00 ➝ $55.00	Low
1/24/2018	Deutsche Bank Aktiengesellschaft	Set Price Target	Buy	$50.00	Low
1/18/2018	Wells Fargo & Company	Set Price Target	Hold	$33.00 ➝ $43.00	Low
1/11/2018	The Goldman Sachs Group	Boost Price Target	Buy	$46.00 ➝ $52.00	High
1/4/2018	Citigroup	Reiterated Rating	Buy ➝ Buy	$48.00 ➝ $58.00	High
1/2/2018	SVB Leerink	Initiated Coverage	Mkt Perform ➝ Market Perform	$44.00	Low
12/26/2017	Cantor Fitzgerald	Set Price Target	Hold	$41.00	Low
12/12/2017	Guggenheim	Initiated Coverage	Buy ➝ Buy	$59.00	Low
12/4/2017	UBS Group	Set Price Target	Buy	$46.00	Low
11/30/2017	Cantor Fitzgerald	Set Price Target	Hold	$34.00	Medium
11/7/2017	Royal Bank of Canada	Boost Price Target	Sector Perform ➝ Sector Perform	$32.00 ➝ $37.00	N/A
10/31/2017	Cantor Fitzgerald	Set Price Target	Hold	$34.00	N/A
10/24/2017	Mizuho	Reiterated Rating	Buy	$37.00	N/A
10/20/2017	Royal Bank of Canada	Set Price Target	Hold	$32.00	N/A
10/6/2017	JPMorgan Chase & Co.	Reiterated Rating	Overweight	$44.00 ➝ $48.00	N/A
10/6/2017	Morgan Stanley	Boost Price Target	Equal Weight	$36.00 ➝ $39.00	N/A
10/5/2017	UBS Group	Reiterated Rating	Buy	$46.00	N/A
10/5/2017	Nomura Instinet	Reiterated Rating	Buy	$37.00	N/A
10/5/2017	Cowen	Reiterated Rating	Market Perform	$30.00 ➝ $36.00	N/A
10/4/2017	Citigroup	Set Price Target	Buy	$42.00	N/A
10/4/2017	Mizuho	Reiterated Rating	Buy	$37.00	N/A
10/4/2017	Wells Fargo & Company	Set Price Target	Hold	$30.00 ➝ $32.00	N/A
10/4/2017	Cantor Fitzgerald	Reiterated Rating	Hold	$34.00	High
10/4/2017	BTIG Research	Boost Price Target	Buy ➝ Buy	$42.00 ➝ $45.00	High
9/29/2017	BMO Capital Markets	Reiterated Rating	Buy	$45.00	Low
9/8/2017	Cantor Fitzgerald	Reiterated Rating	Hold	$34.00	Low
8/22/2017	Argus	Downgrade	Buy ➝ Hold	$47.59 ➝ $29.39	Low
8/20/2017	Mizuho	Reiterated Rating	Buy	$53.00 ➝ $37.00	Low
8/16/2017	Citigroup	Upgrade	Neutral ➝ Buy	$36.00 ➝ $42.00	Medium
8/10/2017	UBS Group	Reiterated Rating	Buy	$50.00 ➝ $46.00	High
8/10/2017	BMO Capital Markets	Reiterated Rating	Outperform	$50.00 ➝ $45.00	High
8/10/2017	Royal Bank of Canada	Reiterated Rating	Sector Perform	$33.00 ➝ $32.00	Low
8/9/2017	Cowen	Reiterated Rating	Hold	$43.00 ➝ $30.00	Medium
8/9/2017	Cantor Fitzgerald	Set Price Target	Hold	$34.00	Medium
8/9/2017	Wells Fargo & Company	Set Price Target	Hold	$34.50 ➝ $30.00	Medium
8/7/2017	Morgan Stanley	Lower Price Target	Equal ➝ Equal Weight	$52.00 ➝ $36.00	Medium
8/4/2017	Royal Bank of Canada	Reiterated Rating	Hold	$41.00 ➝ $33.00	High
8/3/2017	Cowen	Reiterated Rating	Hold	$43.00	High
7/16/2017	Royal Bank of Canada	Set Price Target	Hold	$41.00	Medium
6/16/2017	Cantor Fitzgerald	Initiated Coverage	Neutral ➝ Neutral	$41.00	Low
6/13/2017	Royal Bank of Canada	Reiterated Rating	Hold	$41.00	High
5/31/2017	Wells Fargo & Company	Reiterated Rating	Market Perform	$40.00	Medium
5/22/2017	Barclays	Upgrade	Equal Weight ➝ Overweight	$47.00 ➝ $50.00	Low
5/21/2017	Cowen	Reiterated Rating	Market Perform	$55.00 ➝ $43.00	Medium
5/13/2017	Royal Bank of Canada	Set Price Target	Hold	$41.00	Low
5/11/2017	Royal Bank of Canada	Lower Price Target	Sector Perform	$39.00 ➝ $36.00	Low
5/1/2017	BMO Capital Markets	Initiated Coverage	Outperform	$50.00	Low
4/18/2017	Deutsche Bank Aktiengesellschaft	Lower Price Target	Buy	$52.00 ➝ $51.00	Low
4/17/2017	Royal Bank of Canada	Reiterated Rating	Sector Perform ➝ Sector Perform	$48.00 ➝ $46.00	Low
4/14/2017	Wells Fargo & Company	Reiterated Rating	Market Perform	$40.00	N/A
3/30/2017	SVB Leerink	Reiterated Rating	Outperform	$52.00	Low
3/30/2017	Mizuho	Reiterated Rating	Buy	$53.00	Low
3/30/2017	Royal Bank of Canada	Reiterated Rating	Sector Perform	$48.00	Low
3/20/2017	SVB Leerink	Reiterated Rating	Outperform		Low
3/13/2017	Mizuho	Boost Price Target	Buy ➝ Buy	$47.00 ➝ $53.00	Low
3/11/2017	Barclays	Reiterated Rating	Equal Weight	$44.00 ➝ $47.00	N/A
3/6/2017	SVB Leerink	Reiterated Rating	Outperform	$52.00	N/A
3/3/2017	Guggenheim	Reiterated Rating	Neutral		N/A
3/2/2017	Royal Bank of Canada	Set Price Target	Hold	$44.00 ➝ $48.00	N/A
2/28/2017	Mizuho	Reiterated Rating	Buy	$47.00	N/A

(Data available from 1/18/2017 forward)

News Sentiment Rating

-0.19 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

0 very positive mentions
0 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

6/22/2021

0 very positive mentions
2 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

7/22/2021

0 very positive mentions
3 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

8/21/2021

1 very positive mentions
6 positive mentions
2 negative mentions
1 very negative mentions

Mentions as of

9/20/2021

0 very positive mentions
3 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

10/20/2021

3 very positive mentions
7 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

11/19/2021

4 very positive mentions
11 positive mentions
0 negative mentions
1 very negative mentions

Mentions as of

12/19/2021

0 very positive mentions
10 positive mentions
4 negative mentions
0 very negative mentions

Mentions as of

1/18/2022

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

Negative

reuters.com
12/29/2021
Mylan beats Sanofi appeal in insulin-pen patent fight - Reuters
finance.yahoo.com
12/20/2021
$8.67 Billion Worldwide Lung Cancer Drugs Industry to 2030 - Identify Growth Segments for Investment - ResearchAndMarkets.com - Yahoo Finance
businesswire.com
12/20/2021
$8.67 Billion Worldwide Lung Cancer Drugs Industry to 2030 - Identify Growth Segments for Investment - ResearchAndMarkets.com - Business Wire
seekingalpha.com
12/20/2021
Vifor Pharma settles Injectafer patent litigation - Seeking Alpha

Positive

cnn.com
1/7/2022
Anderson and documentarian Megan Mylan discuss the refugee experience - CNN
globenewswire.com
12/30/2021
Global Hydroxychloroquine Global Market Outlook 2021 to 2030 - GlobeNewswire
businesswire.com
12/30/2021
COPD: 2021 Update Bulletin with Views & Insights from World Leading KOLs; Theravance, Mylan, Novartis, GlaxoSmithKline (GSK), and Mereo Biopharma - ResearchAndMarkets.com - Business Wire
finance.yahoo.com
12/29/2021
Global Branded Generics Market Research Report (2021 to 2026) - by Product, Application, Distribution Channel and Region - Yahoo Finance
finance.yahoo.com
12/24/2021
Global $5.95 Bn Autoinjectors Markets Analysis & Forecasts, 2015-2020, 2020-2025F, 2030F

Very Positive

No very positive mentions tracked during this time.

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health. Its customers include retail pharmacies, wholesalers and distributors, payers, and insurers and governments, as well as institutions, such as hospitals. Mylan N.V. has collaboration and license agreements with Pfizer Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; Fujifilm Kyowa Kirin Biologics Co. Ltd; and Revance Therapeutics, Inc. The company was founded in 1961 and is based in Hatfield, the United Kingdom.

Today's Range

Now: N/A

50 Day Range

MA: $15.57

$14.37

$15.86

52 Week Range

Now: N/A

Volume

14,100,488 shs

Average Volume

6,488,034 shs

Market Capitalization

$8.59 billion

P/E Ratio

29.92

Dividend Yield

N/A

Beta

1.45

Frequently Asked Questions

What sell-side analysts currently cover shares of Mylan?: The following Wall Street research analysts have issued stock ratings on Mylan in the last year:
View the latest analyst ratings for MYL.
What is the current price target for Mylan?: 0 Wall Street analysts have set twelve-month price targets for Mylan in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Mylan in the next year.
View the latest price targets for MYL.
What is the current consensus analyst rating for Mylan?: Mylan currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for MYL.
What other companies compete with Mylan?: Other companies that are similar to Mylan include Johnson & Johnson, Pfizer, AbbVie, Eli Lilly and, Merck & Co., Inc., Bristol-Myers Squibb, Zoetis, Royalty Pharma, Horizon Therapeutics Public, Jazz Pharmaceuticals, Perrigo, Pacira BioSciences, Nektar Therapeutics, Corcept Therapeutics and Supernus Pharmaceuticals.
How do I contact Mylan's investor relations team?: Mylan's physical mailing address is 1000 MYLAN BOULEVARD, CANONSBURG PA, 15317. The company's listed phone number is 724-514-1800 and its investor relations email address is [email protected] The official website for Mylan is www.mylan.com.

NASDAQ:MYL - Mylan Stock Price Target and Predictions

Analyst Price Target for MYL

Current Consensus is N/A

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

-0.19 (Hold)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Mylan?

What is the current price target for Mylan?

What is the current consensus analyst rating for Mylan?

What other companies compete with Mylan?

How do I contact Mylan's investor relations team?